ARTHROPLASTY
Apixiban more effective than enoxaparin for prevention of postoperative thromboembolism
Lancet. 2010 Mar 6;375(9717):807-15.3057 patients scheduled for an elective unilateral or same-day bilateral total knee replacement were randomized to the drug used in prevention of venous thromboembolism, either oral apixiban or subcutaneous enoxaparin. 60 days after the final dose apixiban when compared to enoxaparin was found to be more effective in preventing thrombosis events, had lesser bleeding risks, and had the convenience of twice daily oral administration.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
